185750 — Chong Kun Dang Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapContrarian

Market Cap
KR₩1tn
Enterprise Value
KR₩981bn
Revenue
KR₩2tn

Annual income statement for Chong Kun Dang Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,303,006	1,343,559	1,488,345	1,669,404	1,586,431
Cost of Revenue
Gross Profit	489,140	495,818	542,639	662,202	532,611
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,179,070	1,248,801	1,382,351	1,422,202	1,487,893
Operating Profit	123,936	94,759	105,994	247,203	98,538
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	121,839	80,594	97,165	241,598	102,009
Provision for Income Taxes
Net Income After Taxes	90,405	42,356	79,978	213,602	111,442
Minority Interest
Net Income Before Extraordinary Items
Net Income	91,633	42,720	80,953	212,521	109,073
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	91,633	42,720	80,953	212,521	109,073
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6,634	3,110	6,229	15,861	7,878
Dividends per Share